A PHASE Ib/II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY ACTIVITY AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WITH A K

Brief description of study

This study is for people with advanced or metastatic non-small cell lung cancer (NSCLC) containing a specific KRAS G12C mutation. The study is testing a drug called GDC-6036 (can help fight tumors in patients who have KRAS G12C-positive advanced solid tumors) along with other cancer treatments. At first, they'll see how GDC-6036 works with pembrolizumab in patients with the KRAS G12C mutation and some PD-L1 expression. Other combinations may be later tested based on new data. Participants will take GDC-6036 as pills orally once a day, and they'll get pembrolizumab through a vein every 3 weeks. The study will go on until the cancer gets worse or the treatment stops working, which could be anywhere from 1 day to more than 24 months for each person.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.